


FIG.1A

FIG.1B



400 350 350 300 250 200 150 150 VECTOR HA-BAK CO-TRANSFECTED PLASMID

FIG.1C

FIG.1D






FIG.2



Interaction of Bak with GST-Bcl-x in vitro




FIG.3A

Interaction of Bak with Bcl-x, in COS cells




FIG.3B






FIG.4






FIG.5



BINDING ACTIVITY	+	+/-	ŧ	-1-	ŧ	+	1

PLASMID
Bak APS
Bak AGD
Bax AGD
Bax AGD
Bip1a
Bip1a






FIG.7

COV 0 3 2003 AZ

	50 270	GGG GAC GAC TGA CGC TAT GAC TCA G D D I N R R Y D S	[SEQ. ID NO: 15]	200 210 220 230 240 250 3 *	[SEQ. ID NO: 17] [SEQ. ID NO: (199	260 * CGA CGC [SEQ.ID NO: 19] R R 88 [SEQ.ID NO: 203
	250 260	GAC ATC AAC D I N	ccc ACG P T 103	240 * CTC GCC ATC		ATC AAC I N
		ATC GGG GAC I G D	300 * CTG CAG L Q	230 * 6 GGA CGG CAG 7 G R Q	280 * rc cAG : 0 94	250 * c GGG GAC GAC G D D
	240	CAG GTG GGA CGG CAG CTC GCC ATC ATC Q L A I I	290 * 3 TTG CAG CAC L Q H	220 x G GGG CAG GTG M G Q \	0 * C TCA GAG TTO S E F	220 230 240 * * GTG GGA CGG CAG CTC GCC ATC ATC GGG GA V G R Q L A I I G D
į	230	G GGA CGG CAI	280 290 * GAG TTC CAG ACC ATG TTG CAG E F Q T M L Q	210 * *C AGC ACC AT S S T	270 * SA CGC TAT GAC R Y D	230 * 5A CGG CAG C1 5 R Q L
Bak		1. CAG GT(GAG TT E F	200 * 2. CCT AG 62 P	260 * AAC CGA N R	220 * 3. GTG GG Z4 v G

FIG. 8A

CA2 300 m	[SEQ. ID NO: 21] [SEQ. ID NO. 223
	. 54
280	3 TTC CAG F 0
270	FAT GAC TCA GAG Y D S E
260	AAC CGA CGC TAT N R R Y
250_*	GGG GAC GAC ATC G D D I
	4.


				[SEQ. ID NO: (SEQ.		[SEQ.ID NO: 2 [SEQ.ID NO: (2)
	210	C GAA CTG				73
	200	GGG GAC G D				U
		CGC ATC R I				GT AAC S N
	0 *	AAG CO		•		CTG GAC AGT
	190	CTC AAG L K			210	A CTG
		TGT				C GAA E
- V	O *	C GAG E	S P D	77	- ·	GGG GAC G D
	18	CTG AGC L S			200	ATC GG
		AAG K	\$30 *	CAG Q	190	ည္သ
160 170	170	AAG K	•	C ATG GAG CTG (CTC AAG
		ACC T		3 GAG E		
		6 TC(S	220	C AT(G TGT
	160	A A	AA N	<u>۾</u> *	AGC GAG	
	AG GA Q C		GAC AGT AAC A	1{	CTG A(
Bax		5. 52		O		

FIG. 8B


ig.	[SEQ. ID NO: 27] [SEQ. ID NO: 28]	-b				[SEQ. ID.NO: 29] [SEQ. ID NO: 30]		NO:31]	<u> </u>	[SEQ. ID NO: 33])
	22							22	` `		
	. O. I					SEQ.		[SEQ. 10 [SEQ. 10		SEQ.	
				<u>က</u> _		ٽٽ		ب ب			
				16 AT							
			200	GGG GAC GAG ATG G D E M							
				2 0				は			
•				ဗ္ဟ ပ				<u>ي</u> .			
			190	C AT(0 *	G AG S			
				GCC TGC ATC G A C I			21	GAC GTG AGC D V S			
	•			ည္တမ				Αξ <u>α</u>			
77			CGG CTG (AT(
		180	9 8 8		77	200	GAC GAG ATG (D E M				
				CTG L				GAC D			
	GAC			GCA TTG GCC C	230	AGG GCC CCG CGC CTG R A P R L		CTG GCC TGC ATC GGG L A C I G			
210 * CTG L	5	22	٦ 1		ည္တ ~	190	ATC 1		89		
	GAA E			GCA A		ეე -	~	ည်			
	GGG GAC GAA CTG GAC G D E L D			AGT GAC G	220	GCC A		GCC A			
* 500		Ç	<u>s</u> *	AGT S	23	AGG R		CTG L		ATG M	
	ATC I		160	GAG GGC E G		CTC L	180		200 *	GAG E	
	၁၁ ~			GAG E		AGC		CTG L		GAC D	
190 *	AAG K			ATG M	210	GTG ^		9 P		999	
19	CTC AAG CGC ATC L K R I		150	TGC ATG G		GAC GTG AGC CTC AGG D V S L R	170	11G	8 *	ATC GGG GAC GAG ,	
	8	<u>J</u> a		23			•	13	-	10. 64	
	ع	Bipla		œ.				<u>ه</u>		10.	
		v									

FIG. 8C














FIG.11



Inhibition of Bcl—xL protection of FAS/CHX—treated HcLa cells by Bak GD domain peptides




FIG.12